McMillion Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

McMillion Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-5,790	Closed	-$310K	–	57
2016 Q1	$310K	Sell	5,790 -200	-3%	-$11.7K	0.23%	50
2015 Q4	$393K	Sell	5,990 -1,300	-18%	-$80.3K	0.29%	50
2015 Q3	$412K	Hold	7,290	–	–	0.32%	50
2015 Q2	$431K	Sell	7,290 -125	-2%	-$7.71K	0.27%	54
2015 Q1	$462K	Hold	7,415	–	–	0.28%	52
2014 Q4	$426K	Hold	7,415	–	–	0.24%	55
2014 Q3	$399K	Hold	7,415	–	–	0.23%	57
2014 Q2	$389K	Hold	7,415	–	–	0.22%	58
2014 Q1	$392K	Hold	7,415	–	–	0.24%	57
2013 Q4	$297K	Sell	7,415 -920	-11%	-$36.2K	0.18%	59
2013 Q3	$315K	Sell	8,335 -29,849	-78%	-$1.16M	0.22%	51
2013 Q2	$1.5M	Buy	+38,184	New	+$1.49M	1.1%	36

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

McMillion Capital Management's TEVA Position: Q2 2016 in Review

McMillion Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 5,790 shares — an estimated $310K sold.

McMillion Capital Management first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $1.5M in Q2 2013. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

McMillion Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
McMillion Capital Management sold 5,790 Teva Pharmaceuticals shares in Q2 2016, an estimated $310K.
McMillion Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
McMillion Capital Management's Teva Pharmaceuticals position peaked at $1.5M in Q2 2013.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on McMillion Capital Management's 13F filing for Q2 2016, filed 9 Aug 2016.